[go: up one dir, main page]

SV2010003648A - Inhibidores del receptor de quimioquinas cxcr3 - Google Patents

Inhibidores del receptor de quimioquinas cxcr3

Info

Publication number
SV2010003648A
SV2010003648A SV2010003648A SV2010003648A SV2010003648A SV 2010003648 A SV2010003648 A SV 2010003648A SV 2010003648 A SV2010003648 A SV 2010003648A SV 2010003648 A SV2010003648 A SV 2010003648A SV 2010003648 A SV2010003648 A SV 2010003648A
Authority
SV
El Salvador
Prior art keywords
chemiokin
cxcr3
receiver
inhibitors
azinil
Prior art date
Application number
SV2010003648A
Other languages
English (en)
Inventor
David S Thorpe
Martin Smrcina
Dagmar D Cabel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of SV2010003648A publication Critical patent/SV2010003648A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

ESTA INVENCIÓN SE DIRIGE A UN COMPUESTO 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA O BENZOSULFONAMIDA COMO SE DEFINE EN LA PRESENTE MEMORIA. EL COMPUESTO 3-(AMIDO O SULFAMIDO)-(4-AZINIL SUSTITUIDO)BENZAMIDA O BENZOSULFONAMIDA ES ÚTIL COMO UN INHIBIDOR DEL RECEPTOR DE QUIMIOQUINAS CXCR3, Y PARA PREVENIR O TRATAR UNA ENFERMEDAD MEDIADA POR EL RECEPTOR DE QUIMIOQUINAS CXCR3 O AFECCIÓN RELACIONADA CON LA MISMA EN UN PACIENTE QUE LO NECESITE
SV2010003648A 2008-02-19 2010-08-18 Inhibidores del receptor de quimioquinas cxcr3 SV2010003648A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2973808P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
SV2010003648A true SV2010003648A (es) 2011-01-31

Family

ID=40527535

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003648A SV2010003648A (es) 2008-02-19 2010-08-18 Inhibidores del receptor de quimioquinas cxcr3

Country Status (25)

Country Link
US (1) US8268828B2 (es)
EP (1) EP2262784B1 (es)
JP (1) JP2011512412A (es)
KR (1) KR20100123835A (es)
CN (1) CN102007108A (es)
AR (1) AR070430A1 (es)
AU (1) AU2009215643A1 (es)
BR (1) BRPI0908815A2 (es)
CA (1) CA2715557A1 (es)
CL (1) CL2009000368A1 (es)
CO (1) CO6241113A2 (es)
CR (1) CR11604A (es)
DO (1) DOP2010000254A (es)
EC (1) ECSP10010409A (es)
IL (1) IL207597A0 (es)
MA (1) MA32191B1 (es)
MX (1) MX2010008397A (es)
NI (1) NI201000132A (es)
NZ (1) NZ587380A (es)
PE (1) PE20091576A1 (es)
RU (1) RU2010138577A (es)
SV (1) SV2010003648A (es)
TW (1) TW200948791A (es)
WO (1) WO2009105435A1 (es)
ZA (1) ZA201005314B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
EP2424840B1 (en) 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
KR101251788B1 (ko) 2010-12-06 2013-04-08 기아자동차주식회사 차량 연비 정보 단말표시 시스템 및 그 방법
AU2012284184B2 (en) * 2011-07-18 2017-03-09 Merck Patent Gmbh Benzamides
EP2601950A1 (en) 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
EP2802575B1 (en) 2012-01-10 2017-12-27 Merck Patent GmbH Benzamide derivatives as modulators of the follicle stimulating hormone
ES2632237T3 (es) 2012-02-02 2017-09-12 Idorsia Pharmaceuticals Ltd Compuestos de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados
EP2666769A1 (en) 2012-05-23 2013-11-27 Sanofi Substituted B-amino acid derivatives as CXCR3 receptor antagonist
MX363432B (es) 2013-07-22 2019-03-22 Idorsia Pharmaceuticals Ltd Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona.
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
CA2960275A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
NZ734542A (en) 2015-01-15 2023-02-24 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CN110520127B (zh) * 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
CN115974766B (zh) * 2023-01-04 2025-05-16 中国药科大学 N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719660A (en) 1969-06-13 1973-03-06 Takeda Chemical Industries Ltd 2-furfurylthioinosine-5'-phosphate compounds
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
JP2005530813A (ja) 2002-06-03 2005-10-13 スミスクライン・ビーチャム・コーポレイション イミダゾリウムcxcr3阻害剤
US6734659B1 (en) 2002-06-13 2004-05-11 Mykrolis Corporation Electronic interface for use with dual electrode capacitance diaphragm gauges
CA2598457A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
CN101142209A (zh) 2005-02-16 2008-03-12 先灵公司 具有cxcr3拮抗剂活性的吡嗪基取代的哌嗪-哌啶
KR20070107075A (ko) * 2005-02-16 2007-11-06 쉐링 코포레이션 Cxcr3 길항제 활성을 갖는 신규의 헤테로사이클릭치환된 피리딘 또는 페닐 화합물
WO2007002742A1 (en) 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders
JP2009511582A (ja) 2005-10-11 2009-03-19 シェーリング コーポレイション Cxcr3拮抗薬活性を有する置換複素環式化合物
US20090143413A1 (en) 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
MX2008012161A (es) 2006-03-21 2008-10-03 Schering Corp Compuestos heterociclicos de piridina sustituida con actividad antagonista de cxcr3.
EP2041117B1 (en) 2006-07-14 2012-08-22 Merck Sharp & Dohme Corp. Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3

Also Published As

Publication number Publication date
ECSP10010409A (es) 2010-09-30
DOP2010000254A (es) 2010-08-31
PE20091576A1 (es) 2009-11-05
CR11604A (es) 2010-10-05
KR20100123835A (ko) 2010-11-25
EP2262784B1 (en) 2014-04-16
NI201000132A (es) 2011-03-16
CA2715557A1 (en) 2009-08-27
JP2011512412A (ja) 2011-04-21
MX2010008397A (es) 2010-08-23
TW200948791A (en) 2009-12-01
CL2009000368A1 (es) 2009-06-26
CO6241113A2 (es) 2011-01-20
IL207597A0 (en) 2010-12-30
WO2009105435A1 (en) 2009-08-27
US8268828B2 (en) 2012-09-18
CN102007108A (zh) 2011-04-06
ZA201005314B (en) 2011-03-30
NZ587380A (en) 2011-09-30
MA32191B1 (fr) 2011-04-01
BRPI0908815A2 (pt) 2019-09-24
AR070430A1 (es) 2010-04-07
EP2262784A1 (en) 2010-12-22
RU2010138577A (ru) 2012-03-27
AU2009215643A1 (en) 2009-08-27
US20100305088A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
SV2010003648A (es) Inhibidores del receptor de quimioquinas cxcr3
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
BRPI0917017A2 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CR11303A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20110103A (es) Heteroarilos sustituidos
DOP2012000006A (es) Agonista de gpr119
EA201170832A1 (ru) Пуриновые соединения
CR20110100A (es) Nuevos derivados de sulfamida sustituida
DOP2010000078A (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
BRPI0906522A2 (pt) Sulfonamidas como antagonistas de orexina
ES2399651T8 (es) Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena
SMT201600156B (it) Trattamento dell’osteoartrite
HN2010002558A (es) DERIVADOS DE UREA MACROCICLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa
CR20110332A (es) Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida
CR20110012A (es) Compuestos de fenantrenona, composiciones y métodos
UY32654A (es) Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo
UY31667A1 (es) Inhibidores del receptor de quimioquinas cxcr3
CR20110342A (es) Compuestos ciclopropilo
UY33411A (es) Uso de teriflunomida para el tratamiento de la atrofia cerebral

Legal Events

Date Code Title Description
FD Lapse